AR126854A1 - Compuestos macrocíclicos para el tratamiento de cáncer - Google Patents

Compuestos macrocíclicos para el tratamiento de cáncer

Info

Publication number
AR126854A1
AR126854A1 ARP220102268A ARP220102268A AR126854A1 AR 126854 A1 AR126854 A1 AR 126854A1 AR P220102268 A ARP220102268 A AR P220102268A AR P220102268 A ARP220102268 A AR P220102268A AR 126854 A1 AR126854 A1 AR 126854A1
Authority
AR
Argentina
Prior art keywords
cancer
treatment
macrocyclic compounds
compounds
macrocyclic
Prior art date
Application number
ARP220102268A
Other languages
English (en)
Inventor
Jianguo Chen
Haixia Liu
Hongxia Qiu
Hong Shen
Zhipeng Yan
Beimeng Yang
Xiangyu Yao
Weixing Zhang
Dan Zhao
Wei Zhu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR126854A1 publication Critical patent/AR126854A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (1), en donde de R¹ a R⁵ y de A¹ a A³ son como se describe en la presente, y su sal farmacéuticamente aceptable, y composiciones que incluyen los compuestos y métodos de uso de los compuestos.
ARP220102268A 2021-08-27 2022-08-23 Compuestos macrocíclicos para el tratamiento de cáncer AR126854A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2021115095 2021-08-27
CN2021136793 2021-12-09
CN2022080635 2022-03-14
CN2022098430 2022-06-13

Publications (1)

Publication Number Publication Date
AR126854A1 true AR126854A1 (es) 2023-11-22

Family

ID=83283213

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102268A AR126854A1 (es) 2021-08-27 2022-08-23 Compuestos macrocíclicos para el tratamiento de cáncer

Country Status (4)

Country Link
CN (1) CN117693509A (es)
AR (1) AR126854A1 (es)
TW (1) TW202328140A (es)
WO (1) WO2023025832A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023232776A1 (en) * 2022-06-01 2023-12-07 F. Hoffmann-La Roche Ag Haloindole macrocyclic compounds for the treatment of cancer
WO2023240263A1 (en) * 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024008834A1 (en) * 2022-07-08 2024-01-11 F. Hoffmann-La Roche Ag Macrocycle compounds useful as kras inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3123869A1 (en) 2018-12-21 2020-06-25 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof
PE20221278A1 (es) 2019-11-04 2022-09-05 Revolution Medicines Inc Inhibidores de ras
AU2020377925A1 (en) * 2019-11-04 2022-05-05 Revolution Medicines, Inc. Ras inhibitors
US11739074B2 (en) * 2019-11-04 2023-08-29 Revolution Medicines, Inc. Ras inhibitors
EP4208261A1 (en) * 2020-09-03 2023-07-12 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
CN117683049A (zh) * 2020-09-15 2024-03-12 锐新医药公司 作为ras抑制剂以治疗癌症的吲哚衍生物

Also Published As

Publication number Publication date
WO2023025832A1 (en) 2023-03-02
CN117693509A (zh) 2024-03-12
TW202328140A (zh) 2023-07-16

Similar Documents

Publication Publication Date Title
AR126854A1 (es) Compuestos macrocíclicos para el tratamiento de cáncer
CO2022008997A2 (es) Compuestos tricíclicos sustituidos
CO2022010460A2 (es) Compuestos tricíclicos sustituidos
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
CL2018000952A1 (es) Compuestos útiles como inmunomoduladores
CO2022001357A2 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
PE20212303A1 (es) Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer
PE20181803A1 (es) Inhibidores de mcl-1 macrociclicos para tratar el cancer
PE20221457A1 (es) Degradadores de moleculas pequenas de helios y procedimientos de uso
DOP2021000017A (es) Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos
CU23847B1 (es) 2-piperidinilo bencimidazoles útiles en el tratamiento del crecimiento celular anormal
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
CL2021002621A1 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
CO2019002523A2 (es) Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica
CO2024001285A2 (es) Compuestos tricíclicos como inhibidores de kras
CR20180521A (es) Inhibidores del potenciador del homólogo zeste 2
CL2023000061A1 (es) Macrociclos y su uso
UY39181A (es) COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO
CL2019001023A1 (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia.
MX2023007162A (es) Macrociclos y sus usos.
CO6341625A2 (es) Derivados de indol como agentes anticáncer
CL2023002966A1 (es) Compuestos de oxoisoindolina sustituidos con piridinilo
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
AR126389A1 (es) Compuestos tricíclicos como inhibidores de kras
ECSP22093652A (es) Compuestos de imidazopiridazina y usos de los mismos